Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
| Image |  |
|---|---|
| Description | scientific article published on 01 March 2020 |
| Author/s |
author: Alastair Gray Bernard Zinman Ruth L Coleman Rury Holman David Fitchett |
| Publication date | March 1, 2020 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |